10 research outputs found
Dissociations in the effects of beta2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: Support for the concept of functional selectivity
In neutrophils, activation of the beta2-adrenergic receptor (beta2AR), a Gs-coupled receptor,
inhibits inflammatory responses, which could be therapeutically exploited. The aim of this study was to
evaluate the effects of various beta2AR ligands on adenosine-3',5'-cyclic monophosphate (cAMP)
accumulation and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-induced superoxide anion
(O2*-) production in human neutrophils and to probe the concept of ligand-specific receptor
conformations (also referred to as functional selectivity or biased signaling) in a native cell system.
cAMP concentration was determined by HPLC/tandem mass spectrometry, and O2*- formation was
assessed by superoxide dismutase-inhibitable reduction of ferricytochrome c. beta2AR agonists were
generally more potent in inhibiting fMLP-induced O2*- production than in stimulating cAMP
accumulation. (-)-Ephedrine and dichloroisoproterenol were devoid of any agonistic activity in the
cAMP assay, but partially inhibited fMLP-induced O2*- production. Moreover, (-)-adrenaline was equiefficacious
in both assays whereas the efficacy of salbutamol was more than two-fold higher in the O2*-
assay. In contrast to the agonists, the effects of beta2AR antagonists were comparable between the two
parameters on neutrophils. Differences between the data from neutrophils and recombinant test
systems were observed for the beta2AR agonists as well as for the beta2AR antagonists. Lastly, we
obtained no evidence for an involvement of protein kinase A in the inhibition of fMLP-induced O2*-
production after beta2AR-stimulation, although, in principle, cAMP-increasing substances can inhibit
O2*- production. Taken together, our data corroborate the concept of ligand-specific receptor
conformations with unique signaling capabilities and suggest that the beta2AR inhibits O2*-
production in a cAMP-independent manner
Luciferase reporter gene assay on human, murine and rat histamine H4 receptor orthologs: correlations and discrepancies between distal and proximal readouts
The investigation of the (patho)physiological role of the histamine H4 receptor (H4R) and its validation as a possible drug target in translational animal models are compromised by distinct species-dependent discrepancies regarding potencies and receptor subtype selectivities of the pharmacological tools. Such differences were extremely pronounced in case of proximal readouts, e. g. [32P]GTPase or [35S]GTPγS binding assays. To improve the predictability of in vitro investigations, the aim of this study was to establish a reporter gene assay for human, murine and rat H4Rs, using bioluminescence as a more distal readout. For this purpose a cAMP responsive element (CRE) controlled luciferase reporter gene assay was established in HEK293T cells, stably expressing the human (h), the mouse (m) or the rat (r) H4R. The potencies and efficacies of 21 selected ligands (agonists, inverse agonists and antagonists) were determined and compared with the results obtained from proximal readouts. The potencies of the examined ligands at the human H4R were consistent with reported data from [32P]GTPase or [35S]GTPγS binding assays, despite a tendency toward increased intrinsic efficacies of partial agonists. The differences in potencies of individual agonists at the three H4R orthologs were generally less pronounced compared to more proximal readouts. In conclusion, the established reporter gene assay is highly sensitive and reliable. Regarding discrepancies compared to data from functional assays such as [32P]GTPase and [35S]GTPγS binding, the readout may reflect multifactorial causes downstream from G-protein activation, e. g. activation/amplification of or cross-talk between different signaling pathways
Akinetic view of GPCR allostery and biased agonism
G-protein-coupled receptors (GPCRs) are one of the most tractable classes of drug targets. These dynamic proteins can adopt multiple active states that are linked to distinct functional outcomes. Such states can be differentially stabilized by ligands interacting with the endogenous agonist-binding orthosteric site and/or by ligands acting via spatially distinct allosteric sites, leading to the phenomena of 'biased agonism' or 'biased modulation'. These paradigms are having a major impact on modern drug discovery, but it is becoming increasingly apparent that 'kinetic context', at the level of both ligand-receptor and receptor-signal pathway kinetics, can have a profound impact on the observation and quantification of these phenomena. The concept of kinetic context thus represents an important new consideration that should be routinely incorporated into contemporary chemical biology and drug discovery studies of GPCR bias and allostery